Viking Therapeutics: A Stock at a Crossroads Amid Obesity Drug Ambitions

Viking Therapeutics US92686J1060

Shares of Viking Therapeutics have experienced a notable pullback following a strong start to the year. Despite a series of positive corporate updates, the stock declined 7.21% to $31.86 in a recent session and is now down approximately 10% since January. This performance lags the S&P 500, which has posted modest gains over the same period, raising questions about the disconnect between recent news and share price weakness.

The equity has exhibited significant volatility, with recent trading sessions seeing intraday swings exceeding 10%. On January 14 alone, the stock traded between $30.69 and $36.00. These sharp movements underscore market uncertainty ahead of critical Phase 3 data readouts and potential partnership announcements. Furthermore, the entire obesity drug development sector has garnered increased attention due to heightened acquisition speculation. A key catalyst was Pfizer's approximately $10 billion acquisition of Metsera in November 2025, which refocused potential buyers on obesity developers like Viking.

For Viking, several potential share price drivers remain in play: continued progress in its VANQUISH clinical program, decisions regarding the commercial strategy for its lead drug candidate, and potential transaction activity involving larger pharmaceutical companies.

Robust Clinical Data for VK2735

Viking entered January with considerable momentum, bolstered by strong clinical results. On January 12, the company published peer-reviewed Phase 2 data from its VENTURE study for its obesity drug candidate, VK2735, in the journal Obesity.

The key findings included:
* Weight reduction of up to 14.7% from baseline after 13 weeks of treatment.
* A dual GLP-1/GIP receptor agonist mechanism of action.
* Efficacy data showing no evidence of a plateau effect.

Despite this validation through a reputable publication, the share price has retreated from $35.42 at the start of the year to current levels, significantly underperforming the broader market. This decline highlights the extent to which high expectations for the project were already reflected in the stock's valuation.

Recent Corporate Milestones

• January 12: Publication of Phase 2 VENTURE data demonstrating up to 14.7% weight loss.
• January 8: Completion of patient recruitment for the VK2735 maintenance dose study.
• January 7: Appointment of Neil Aubuchon as Chief Commercial Officer.
• January 5: Corporate presentation at the 44th J.P. Morgan Healthcare Conference.

Strategic Positioning and Partnership Potential

At the J.P. Morgan Healthcare Conference, CEO Brian Lian outlined the competitive landscape of the obesity market, which is estimated to reach an annual volume of around $150 billion in the long term. Lian emphasized that strategic interest from large pharmaceutical companies in obesity therapeutics is broader than public transactions suggest, with firms evaluating both early-stage projects at lower valuations and more established drug candidates justifying significantly higher prices.

Viking has expressed openness to partnerships but has simultaneously stressed its capability to independently advance VK2735 through Phase 3 trials if necessary. This stance keeps both strategic options—collaboration or independent commercialization—available to the company.

Advancing the Phase 3 VANQUISH Program

The registration-focused VANQUISH program for VK2735 is progressing according to plan.
* VANQUISH-1: Patient recruitment was completed ahead of schedule.
* VANQUISH-2: Recruitment completion is anticipated in the first quarter of 2026.

Concurrently, Viking is developing both subcutaneous and oral formulations of VK2735. This dual approach addresses different treatment scenarios and expands the drug's potential market opportunities.

Financial Profile and Divergent Analyst Views

Viking currently holds a market capitalization of approximately $3.6 billion. The company reported a net loss of $237.4 million over the past twelve months, with no revenue generated—a typical profile for a biotechnology firm in the clinical development stage.

Wall Street analysts present a mixed picture. The consensus price target stands at $93.39, far above the current trading price. In November 2025, Canaccord Genuity reaffirmed its "Buy" rating and raised its price target to $107. Conversely, Zacks currently rates the stock a "Sell," citing an expected earnings per share figure of -$0.89 for the coming quarter, which would represent a year-over-year decline of 178%. This tension between optimistic long-term targets and weak short-term metrics reflects the classic risk-reward profile of pre-revenue biotech investments.

@ boerse-global.de | US92686J1060 VIKING